Rare Lymphomas

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity.

I General: Pathology. - Cytogenetics. - Molecular Genetics. - Signal Pathways. - II Disease-specific: T-NHL: Acute T-cell leukemia. - Anaplastic lymphoma. - Nasal/NK-cell lymphoma. - Cutaneous T-cell lymphoma. - B-NHL: Adult Burkitt. - Primary Mediastinal Lymphoma. - CNS Lymphoma. - HIV-Associated lymphoma. - Marginal Zone Lymphoma. - MALT. - MCL. - Waldenstroem. - PLL. - Llymphocyte Predominant Hodgkin. - Cutaneous B-cell lymphoma.